This application discloses the use of
itaconic acid derivatives in the preparation of drugs for treating candidemia, belonging to the field of
biomedical technology. The
itaconic acid derivatives proposed in this application are dimethyl
itaconic acid and / or 4-octyl itaconic acid. Dimethyl itaconic acid exhibits a
dose-dependent
therapeutic effect in model mice, with an optimal
dose of 1200 mg / kg improving
survival rate and reducing
kidney damage; 4-octyl itaconic acid can enhance the anti-
Candida albicans ability of macrophages and regulate the expression of
inflammatory factors. The application of the itaconic acid derivatives proposed in this application in the treatment of candidemia works through immunomodulation, circumventing fungal resistance. Furthermore, the drugs are low in
toxicity, have good
biocompatibility, and use a universal
experimental system, providing a new approach for the
clinical treatment of candidemia with broad application prospects. This application also protects pharmaceutical compositions for treating candidemia with dimethyl itaconic acid and / or 4-octyl itaconic acid as active ingredients.